Full-Time

Senior Principal Scientist

Posted on 8/4/2025

Xaira Therapeutics

Xaira Therapeutics

51-200 employees

AI-powered protein design for therapeutics

Compensation Overview

$173k - $230k/yr

+ Bonus + Equity

San Bruno, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Machine Learning
Requirements
  • Ph.D. in Bioengineering, Molecular Biology, Biophysics, or a related field with 8+ years of post-doctoral experience in an academic or industry setting, focusing on technology development.
Responsibilities
  • Spearhead the identification, evaluation, and implementation of cutting-edge technologies to enhance the speed, scale, and quality of biologics discovery campaigns.
  • Act as a key individual contributor, providing hands-on expertise in the lab to de-risk new technologies and establish robust workflows in areas such as high-throughput screening, microfluidics, advanced imaging, and novel molecular biology tools.
  • Build, lead, mentor, and manage a dedicated team of 2 Ph.D.-level scientists, fostering a culture of innovation, collaboration, and scientific rigor.
  • Partner closely with multidisciplinary teams, including drug discovery, protein sciences, AI/ML, and biology, to define key scientific questions and integrate new technological capabilities into discovery workflows.
  • Drive the design, execution, and optimization of sophisticated screening assays and technology development projects that directly impact program goals.
  • Develop and champion the strategic vision for technology innovation within biologics discovery, staying current with the latest scientific and technological advancements.
  • Present scientific findings, project progress, and strategic proposals to internal and external stakeholders, contributing to publications and intellectual property filings.
  • Oversee experimental design, protocol development, and resource allocation for the Exploration Technology team to ensure project milestones and scientific objectives are met.
Desired Qualifications
  • Experience onboarding new platforms that have tangibly impacted discovery programs.
  • Track record of publications and intellectual property filings related to technology development.
  • Experience working at the interface of biology and data science; ability to collaborate effectively with AI/ML and computational scientists.

Xaira Therapeutics uses artificial intelligence to transform drug discovery and development. It builds a pipeline of protein- and antibody-based therapeutics by combining generative AI models from the IPD lab (notably RFdiffusion and RFantibody) with large, multidimensional biological data. The company designs novel proteins and antibodies from scratch to target difficult, previously undruggable biology, then validates and evolves these molecules through iterative data generation that improves its biological foundation models. Unlike many entrants that offer research services, Xaira aims to own and advance its own therapeutic pipeline across multiple modalities, rather than solely providing platforms. The goal is to deliver effective new medicines faster and with a lower chance of failure by integrating AI-driven design, expansive data, and expert leadership.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$1B

Headquarters

Brisbane, California

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • Rachel Lane closed Genentech and Sanofi partnerships at Belharra, now drives Xaira deals.
  • Focus on inflammatory diseases aligns with high-priority pharma therapeutic targets.
  • 73,075 sq ft San Francisco expansion by July 2025 supports rapid scaling.

What critics are saying

  • Isomorphic Labs' $600M Series A in March 2025 erodes Xaira's first-mover edge.
  • Xaira's $1B burn rate triggers liquidity crisis without Series B by mid-2027.
  • Public X-Atlas release lets Recursion reverse-engineer models within 12 months.

What makes Xaira Therapeutics unique

  • Xaira leverages RFdiffusion and RFantibody from David Baker's IPD for de novo protein design.
  • X-Cell model with 4.9 billion parameters predicts perturbations on 25.6 million transcriptomes.
  • X-Atlas/Pisces dataset is largest public genome-wide CRISPRi Perturb-seq resource.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

2%
Business Wire
Mar 26th, 2026
Xaira Therapeutics appoints Rachel Lane as SVP to lead business development and AI drug discovery partnerships

Xaira Therapeutics has appointed Rachel Lane as Senior Vice President of Business Development and Operations. She will oversee business development strategy and drive partnerships integrating machine learning with therapeutic development. Lane brings over a decade of biotech leadership experience as an operator and investor. Most recently, she served as Chief Business Officer at Belharra Therapeutics, where she closed major platform partnerships with Genentech and Sanofi. She previously worked at Versant Ventures and holds a PhD in Molecular Genetics and Cell Biology. This month, Xaira launched X-Cell, its virtual cell model trained on 25.6 million perturbed single-cell transcriptomes. The 4.9 billion-parameter model predicts outcomes of genetic perturbations, marking progress towards transforming drug discovery into a predictive engineering discipline.

Endpoints News
Mar 18th, 2026
With its first AI model release, xaira tests scaling laws in virtual cells.

With its first AI model release, xaira tests scaling laws in virtual cells. Senior biopharma correspondent. Biotech's best-funded AI startup detailed its first AI model on Tuesday, giving a glimpse at what it's been doing since launching out of stealth nearly... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Fierce Biotech
Mar 17th, 2026
Xaira COO reveals $1B AI biotech targets inflammatory and immunological diseases

Xaira Therapeutics' Chief Operating Officer Jeff Jonker has revealed the AI-driven biotech is focusing its research and development efforts on inflammatory and immunological science. The disclosure marks the first detailed insight into how the company is deploying its capital since raising $1 billion in 2024. The secretive biotech has remained largely quiet about its operations since the fundraise. Jonker's comments to Fierce Biotech provide the first public glimpse into Xaira's strategic priorities as it applies artificial intelligence to drug discovery in areas the pharmaceutical industry considers high-priority therapeutic targets.

Business Wire
Mar 17th, 2026
Xaira Therapeutics launches X-Cell virtual cell model trained on 25.6M single-cell transcriptomes

Xaira Therapeutics has launched X-Cell, its first virtual cell model, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset ever reported. The dataset contains 25.6 million perturbed single-cell transcriptomes across seven cellular contexts, more than three times larger than Xaira's previous dataset. X-Cell uses a diffusion language model architecture with 4.9 billion parameters, making it the largest causal perturbation model to date. Unlike traditional autoregressive models, it iteratively refines predictions by progressively replacing control gene expression values with perturbed values, improving accuracy with each step. The model demonstrates state-of-the-art performance in predicting genetic perturbation outcomes, including unseen experiments across different cell types and laboratories. Xaira is making a subset of the dataset and model available to the scientific community.

Business Wire
Jul 9th, 2025
Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer

Xaira Therapeutics announces the appointment of Jeff Jonker as President and Chief Operating Officer.

INACTIVE